好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of COVID-19 and vaccines in myasthenia gravis: experience from an Italian cohort
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (9:00 AM-5:00 PM)
409

Since COVID-19 infection became a global public health problem, finding a treatment has been an emergency and vaccines are considered the only solution. 
In the last months, a big amount of data has been published on COVID-19 and vaccines and are currently available for the general population, but little is still known regarding patients with myasthenia gravis.

We performed a cross-sectional study among a cohort of patients with Myasthenia gravis attending to the Neuromuscular Clinic of the University Hospital “Paolo Giaccone” of Palermo. Patients underwent a telephonic interview through a dedicated questionary about COVID-19 infection, vaccinations, and their effects on MG.

In our cohort 9 patients resulted positive to SARS-COV2 infection, 4 patients died for COVID-19, a patient worsened for MG, requiring respiratory support, whereas 3 patients were asymptomatic. Fifty-three patients completed the vaccination with minor side effects in 24 cases. Seventeen patients presented a worsening of symptoms.
The reduced number of adverse events in our population suggests that vaccines for SARS-cov2 are safe in myasthenic patients that could take advantage of vaccination avoiding life-threatening complications such as myasthenic crisis and COVID-19 pneumonia. The continuation of the regular and periodic clinical follow-up will provide us data on the real effectiveness of vaccine prevention in the myasthenic population
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Pignolo Antonia (Università di Palermo) Ms. Antonia has nothing to disclose.
No disclosure on file
No disclosure on file
Brigida Fierro (Smithkline Beechman) No disclosure on file
Filippo Brighina, MD (University of Palermo) Prof. Brighina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Prof. Brighina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Prof. Brighina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly. Prof. Brighina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam Pharmaceuticals.